A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512734-15-00

Acronym

67856633LYM1001

Enrollment

Registered

2024-07-22

Start date

2019-10-23

Completion date

2025-03-17

Last updated

2024-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin lymphoma and chronic lymphocytic leukemia

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Greece

None listed

Source: EU CTIS · Data processed: Feb 4, 2026